British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.
Br J Dermatol. 2020 Mar 18;:
Authors: Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF, British Association of Dermatologists’ Clinical Standards Unit
Abstract
The overall aim of the guideline is to provide up-to-date, evidence-based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), IL17RA (brodalumab) and IL23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis.
PMID: 32189327 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF, British Association of Dermatologists’ C Tags: Br J Dermatol Source Type: research
More News: Arthritis | Children | Dermatology | Enbrel | Humira | Psoriasis | Psoriatic Arthritis | Remicade | Rheumatology | Skin | Stelara | UK Health